百济神州(06160) - 2025 Q1 - 季度业绩

Financial Performance - Total revenue for Q1 2025 reached $1.12 billion, a 49$751.65 million in Q1 2024[8] - Product revenue for Q1 2025 was $1.11 billion, up 48$746.92 million in the same period last year[8] - GAAP operating profit for Q1 2025 was $11.1 million, a significant improvement from a loss of$261.35 million in Q1 2024, marking a 104% change[8] - Adjusted operating profit for Q1 2025 was $139.36 million, compared to a loss of$147.34 million in the previous year, representing a 195% increase[8] - The company achieved its first GAAP quarterly profit in Q1 2025, with a GAAP net profit of $1.27 million, compared to a loss of$251.15 million in Q1 2024[8] - The company reported a net profit of $0.00 per share in Q1 2025, an improvement from a loss of$0.19 per share in the same period last year[14] - The net profit for Q1 2025 was $1,270,000, a turnaround from a net loss of$251,150,000 in Q1 2024[32] Sales and Market Performance - Global sales of Brukinsa (Zebutinib) amounted to $792 million, reflecting a 62$563 million in product revenue for Q1 2025, up from $351 million in the same quarter last year[9] - Baiyueze® sales in the U.S. reached$563 million in Q1 2025, a 60% increase year-over-year, primarily due to increased demand in CLL indications[13] - Baiyueze® is now approved in 75 markets globally, with recent expansions in Japan, Europe, and Brazil[17] Expenses and Costs - R&D expenses for Q1 2025 were $481.9 million, a 5$460.6 million in Q1 2024; adjusted R&D expenses rose 4% to 421.2 million[11] - SG&A expenses in Q1 2025 were 459.3 million, up 7% from 427.4 million in Q1 2024, with SG&A expenses accounting for 41% of product revenue, down from 57% year-over-year[12] - Operating expenses totaled 941,175,000 in Q1 2025, compared to $888,065,000 in Q1 2024, marking an increase of approximately 6$2,530,591,000, a slight decrease from $2,638,747,000 as of December 31, 2024[33] - Total assets amounted to$5,841,526,000 as of March 31, 2025, down from $5,920,910,000 at the end of 2024[33] - Net cash provided by operating activities was$44,082 thousand in Q1 2025, a significant improvement from a net cash used of $308,572 thousand in Q1 2024[34] - Cash used in investing activities was$121,941 thousand in Q1 2025, compared to $209,831 thousand in Q1 2024[34] Future Plans and Developments - The company plans to hold an investor R&D day on June 26, 2025, to discuss advancements in its late-stage hematologic and solid tumor pipeline[7] - The company expects to report proof of concept data in various projects related to antibody-drug conjugates, multispecific antibodies, and targeted protein degradation throughout the year[7] - The company expects to complete mid-term analysis for the Phase 3 MANGROVE trial for MCL treatment in the second half of 2025[23] - The company plans to submit a global accelerated approval application for Sotoclar in R/R MCL following data readout from a Phase 2 trial anticipated in late 2025[26] - Baiyueze® tablet formulation is anticipated to receive FDA and EU approval in the second half of 2025[23] Corporate Changes - The company has received shareholder approval to adopt a new English name, BeOne Medicines Ltd., and relocate its registered office to Switzerland[7] - The company has received shareholder approval to change its name to BeOne Medicines Ltd. and relocate its registered office to Switzerland, expected to be completed later this year[26]